SR One related stories
All articles and analysis
Spero Therapeutics fetches $30 mln Series ACambridge, Massachusetts-based Spero Therapeutics LLC, a biopharmaceutical company that focuses on treating bacterial infections, has raised $30 million in Series A funding. Lundbeckfond Ventures led the round with participation from other investors that included Merck Research Ventures, The Kraft Group, Atlas Venture, SR One and Partners Innovation Fund. In conjunction with the funding, Lundbeckfond Ventures’s Casper Breum and Merck’s Dr. Josh Resnick have been added to Spero's board.
- IPO Profile: HTG Molecular Diagnostics Inc
The medtech company raised $50 million in its offering
- CRISPR Therapeutics raises $64 mln
CRISPR Therapeutics said Wednesday it raised $64 million in financing, including $35 million in a Series A and $29 million in a Series B. Strategic investors, SR One and Celgene Corp., led the rounds while new investors New Enterprise Associates and Abingworth, alongside the Company’s founding investor, Versant Ventures, also participated. CRISPR Therapeutics, of Basel, Switzerland, is a biopharmaceutical company.
Top Canadian VC deals from the first quarterIn the coming weeks, the Canadian Venture Capital & Private Equity Association (CVCA) and Thomson Reuters will issue their reports on Canadian venture capital market activity in the first quarter of 2015. In the meantime, peHUB Canada has compiled a list of the likely top 10 (disclosed) financings completed between January and March.
- True North Therapeutics scores $35 mln Series B
San Francisco-based biotech company True North Therapeutics has closed $35 million in Series B funding. OrbiMed led the round with participation from return backers Kleiner Perkins Caufield & Byers, MPM Capital, SR One and Baxter Ventures.
- Thrasos Innovation raises $21 mln
Thrasos Innovation has raised a $21 million financing round from investors including the Fonds de solidarité FTQ, BDC Venture Capital and SR One. Thrasos, of Montreal, is biotech focused on developing therapies to treat kidney disease.
BDC Capital, SR One lead $21 mln Series D round for Thrasos TherapeuticsThrasos Therapeutics, a Montréal-based biotherapeutics company focused on delivering new treatments for kidney disease, has raised $21 million in a Series D round. BDC Capital and SR One led the financing with the participation of all existing investors, which include Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures. With the deal's closing, BDC Managing Partner Ela Borenstein has joined Thrasos' board of directors. Update: The company said it will use the new investment's proceeds to advance its technology and to position its lead program for the next step in clinical development.
- BDC Capital and SR One leads Series D round for Thrasos
Montreal-based Thrasos Therapeutics, a biotherapeutics company focused on kidney disease, has closed $21 million in Series D funding. BDC Capital and SR One led the round. In conjunction with the funding, Ela Borenstein, a manager partner at BDC, has been added to the Thrasos board of directors.
- Nimbus Therapeutics pulls in $43 mln
Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company's previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.
Germany leads deal activity in OctoberA total of 78 European companies raised about $290 million in disclosed deal values in the month